[go: up one dir, main page]
Skip to main content

Articles

Page 1 of 110

  2. Despite advances in breast cancer imaging, reliable detection of sentinel lymph node (SLN) metastasis remains challenging. This study aimed to determine the ability of immuno-positron emission tomography (PET)...

    Authors: Takeshi Usui, Tomohiro Miyake, Tadashi Watabe, Hiroki Kato, Yukie Yoshii, Sadahiro Naka, Kaori Abe, Misato Masuyama, Nanae Masunaga, Tetsuhiro Yoshinami, Masami Tsukabe, Yoshiaki Sota, Tomonori Tanei, Masafumi Shimoda and Kenzo Shimazu
    Citation: Breast Cancer Research 2025 27:33
    Content type: Research Published on:

  3. Lipid metabolic reprogramming is increasingly recognized as a hallmark of endocrine resistance in estrogen receptor-positive (ER+) breast cancer. In this study, we investigated alterations in lipid metabolism ...

    Authors: Ashley V. Ward, Duncan Riley, Kirsten E. Cosper, Jessica Finlay-Schultz, Heather M. Brechbuhl, Andrew E. Libby, Kaitlyn B. Hill, Rohan R. Varshney, Peter Kabos, Michael C. Rudolph and Carol A. Sartorius
    Citation: Breast Cancer Research 2025 27:32
    Content type: Research Published on:

  4. Breast cancer (BRCA) is a common malignant tumor, and its immune microenvironment plays a crucial role in disease progression. In this research, we utilized single-cell RNA sequencing and bulk RNA sequencing t...

    Authors: Sixuan Wu, Baohong Jiang, Zhimin Li, Yuanbin Tang, Lunqi Luo, Wenjie Feng, Yiling Jiang, Yeru Tan and Yuehua Li
    Citation: Breast Cancer Research 2025 27:31
    Content type: Research Published on:

  5. The aim of this study was to develop and validate a deep learning radiomics (DLR) model based on longitudinal ultrasound data and clinical features to predict pathologic complete response (pCR) after neoadjuva...

    Authors: Xiaodan Feng, Yan Shi, Meng Wu, Guanghe Cui, Yao Du, Jie Yang, Yuyuan Xu, Wenjuan Wang and Feifei Liu
    Citation: Breast Cancer Research 2025 27:30
    Content type: Research Published on:

  6. Radiomics and AI have been widely used in breast cancer imaging, but a comprehensive systematic analysis is lacking. Therefore, this study aims to conduct a bibliometrics analysis in this field to discuss its ...

    Authors: Xinyu Wu, Yufei Xia, Xinjing Lou, Keling Huang, Linyu Wu and Chen Gao
    Citation: Breast Cancer Research 2025 27:29
    Content type: Research Published on:

  8. CALGB 40903 (Alliance) was a phase II single arm multicenter trial conducted in postmenopausal patients diagnosed with estrogen-receptor (ER) positive breast ductal carcinoma in situ (DCIS) without invasion. P...

    Authors: Jeffrey R. Marks, Dadong Zhang, Timothy Hardman, Yunn-yi Chen, Allison Hall, Lunden Simpson, Tina Hieken, Isabelle Bedrosian, Elissa Price, Jeff Sheng, Yanwan Dai, Marissa Lee, Alexander B. Sibley, Kouros Owzar and E. Shelley Hwang
    Citation: Breast Cancer Research 2025 27:26
    Content type: Research Published on:

  9. Apolipoprotein Ɛ4 genotype (APOE4) has been associated with cancer-related cognitive impairment, but its interaction with treatments remains unclear. This longitudinal study aims to evaluate the association be...

    Authors: Mylène Duivon, François Christy, Emilie Thomas, Justine Lequesne, Hélène Castel, Catherine Gaudin, Dominique Delmas, Sandrine Boyault, Olivier Rigal, Chayma Bousrih, Christelle Lévy, Florence Lerebours, Antonio Di Meglio, Patricia A. Ganz, Kathleen Van Dyk, Ines Vaz Luis…
    Citation: Breast Cancer Research 2025 27:25
    Content type: Brief Report Published on:

  10. Angiogenic activity of cancerous breast tumors can be impacted by neoadjuvant chemotherapy (NAC), thus potentially serving as a marker for response monitoring. While different imaging modalities can aid in eva...

    Authors: Soroosh Sabeti, Nicholas B. Larson, Judy C. Boughey, Daniela L. Stan, Malvika H. Solanki, Robert T. Fazzio, Mostafa Fatemi and Azra Alizad
    Citation: Breast Cancer Research 2025 27:24
    Content type: Research Published on:

  11. 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (...

    Authors: Natasha B. Hunter, Lanell M. Peterson, Jennifer M. Specht, David A. Mankoff, Mark Muzi, Delphine L. Chen, William R. Gwin, Shaveta Vinayak, Nancy E. Davidson and Hannah M. Linden
    Citation: Breast Cancer Research 2025 27:23
    Content type: Research Published on:

  12. New data show that not only HER2-overexpressing breast cancer (BC) tumors but also HER2-low tumors, classically considered as HER2-negative, respond to HER2-targeting antibody–drug-conjugates. Our objective wa...

    Authors: Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Rolf Mahlberg, Wolfram Malter, Toralf Reimer, Benno Nuding…
    Citation: Breast Cancer Research 2025 27:22
    Content type: Research Published on:

  13. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer, yet its response to traditional chemotherapy remains limited, ...

    Authors: Lina Zhang, Yueping Liu, Chao Yang, Jie Ma, Yuntao Li, Ruizhen Luo, Jianjun Han, Xiaochun Wang, Zhisheng Zhang, Li Ma, Haifeng Cai, Xiangshun Kong, Zunyi Wang, Xinping Zhou, Jiajie Shi, Yanshou Zhang…
    Citation: Breast Cancer Research 2025 27:21
    Content type: Research Published on:

  14. Breast cancer is the leading cause of female mortality worldwide. (SET And MYND Domain Containing 4) SMYD4 has been reported to be a tumour suppressor. However, the molecular mechanism of SMYD4 remains unclear.

    Authors: Jin-Shuo Yang, Jun-Ming Cao, Rui Sun, Xue-Jie Zhou, Zhao-Hui Chen, Bo-Wen Liu, Xiao-Feng Liu, Yue Yu and Xin Wang
    Citation: Breast Cancer Research 2025 27:20
    Content type: Research Published on:

  15. Breast Cancer (BC) is the most common type of cancer in women around the world and 70% of cases are hormone-receptor positive (HR+). In 40% of cases, a key mechanism of endocrine resistance to the standard fir...

    Authors: Morgane Lopez, Laurie Spehner, Fabrice André, Julien Viot, Evan Seffar, Amélie Marguier, Elsa Curtit, Guillaume Meynard, Erion Dobi, Sylvain Ladoire, Romain Boidot, Romain Loyon, Valentin Derangere, François-Clément Bidard, Christophe Borg, Laura Mansi…
    Citation: Breast Cancer Research 2025 27:19
    Content type: Research Published on:

  16. Mammographic breast density (MBD), a strong predictor of breast cancer, is highly influenced by body mass index (BMI) in childhood and early adulthood, but the mechanisms underlying these associations are not ...

    Authors: Kayla R. Getz, Myung Sik Jeon, Lili Liu, Lei Liu, Haixiang Zhang, Chongliang Luo, Jingqin Luo and Adetunji T. Toriola
    Citation: Breast Cancer Research 2025 27:18
    Content type: Research Published on:

  17. Tumour vascular density assessed from CD-31 immunohistochemistry (IHC) images has previously been shown to have prognostic value in breast cancer. Current methods to measure vascular density, however, are time...

    Authors: Tristan Whitmarsh, Wei Cope, Julia Carmona-Bozo, Roido Manavaki, Stephen-John Sammut, Ramona Woitek, Elena Provenzano, Emma L. Brown, Sarah E. Bohndiek, Ferdia A. Gallagher, Carlos Caldas, Fiona J. Gilbert and Florian Markowetz
    Citation: Breast Cancer Research 2025 27:17
    Content type: Research Published on:

  18. Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment risk factors for pn...

    Authors: Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays and Kevin Ho
    Citation: Breast Cancer Research 2025 27:16
    Content type: Research Published on:

  19. CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhi...

    Authors: Qianfeng Shi, Wang Yang, Yiye Ouyang, Yujie Liu and Zijie Cai
    Citation: Breast Cancer Research 2025 27:15
    Content type: Research Published on:

    The Correction to this article has been published in Breast Cancer Research 2025 27:28

  20. Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that ...

    Authors: Femke A. I. Ehlers, Katie E. Blise, Courtney B. Betts, Shamilene Sivagnanam, Loes F. S. Kooreman, E. Shelley Hwang, Gerard M. J. Bos, Lotte Wieten and Lisa M. Coussens
    Citation: Breast Cancer Research 2025 27:14
    Content type: Research Published on:

  21. Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) after neoadjuvant chemotherapy. Individualized pCR prediction based on clinical informa...

    Authors: Lothar Häberle, Ramona Erber, Paul Gass, Alexander Hein, Melitta Niklos, Bernhard Volz, Carolin C. Hack, Rüdiger Schulz-Wendtland, Hanna Huebner, Chloë Goossens, Matthias Christgen, Thilo Dörk, Tjoung-Won Park-Simon, Andreas Schneeweiss, Michael Untch, Valentina Nekljudova…
    Citation: Breast Cancer Research 2025 27:13
    Content type: Research Published on:

  22. The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palb...

    Authors: A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron…
    Citation: Breast Cancer Research 2025 27:12
    Content type: Research Published on:

  23. Obesity is a modifiable risk factor for breast cancer. Yet, how obesity contributes to cancer initiation is not fully understood. The goal of this study was to determine if the body mass index (BMI) and metabo...

    Authors: Mohamed Gaber, Arnaud Quentel, Julia Holmes, Cassandra Lepetit, Hana Triki, Adam Wilson, Valerie Payne, Iliana Tenvooren, Cloé Dehours, Abigail Peoples, Mary L. Duet, Adam J. Katz, Thierry Pécot, Gwenola Bougras-Cartron, Pierre-François Cartron, Katherine L. Cook…
    Citation: Breast Cancer Research 2025 27:11
    Content type: Research Published on:

  24. Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen rec...

    Authors: K. S. Young, G. R. Hancock, E. C. Fink, A. Zigrossi, B. Flowers, D. A. Cooper, V. T. Nguyen, M. C. Martinez, K. S. Mon, M. Bosland, D. R. Zak, A. P. Runde, M. N. Sharifi, I. Kastrati, D. D. L. Minh, S. Kregel…
    Citation: Breast Cancer Research 2025 27:10
    Content type: Research Published on:

  25. Tumour DNA methylation has been investigated as a potential marker for breast cancer survival, but findings often lack replication across studies.

    Authors: Elaheh Zarean, Shuai Li, Ee Ming Wong, Enes Makalic, Roger L. Milne, Graham G. Giles, Catriona McLean, Melissa C. Southey and Pierre-Antoine Dugué
    Citation: Breast Cancer Research 2025 27:9
    Content type: Research Published on:

  26. Poly (ADP-Ribose) polymerase inhibitors are approved for treatment of tumors with BRCA1/2 and other homologous recombination repair (HRR) mutations. However, clinical responses are often not durable and treatm...

    Authors: Romain Pacaud, Scott Thomas, Sibapriya Chaudhuri, Ann Lazar, Luika A. Timmerman and Pamela N. Munster
    Citation: Breast Cancer Research 2025 27:8
    Content type: Research Published on:

  27. Hereditary predisposition to breast and ovarian cancer syndrome (HBOC) is a pathological condition with increased cancer risk, including breast (BC), ovarian cancer (OC), and others. HBOC pathogenesis is cause...

    Authors: Dione Aguilar, María Lourdes Garza-Rodríguez, Carolina Elizabeth Muñiz-Garza, Fernando Alcorta Nuñez, Cynthia Mayte Villarreal-Garza, Oscar Vidal-Gutiérrez, Diana Cristina Pérez-Ibave and Carlos Horacio Burciaga-Flores
    Citation: Breast Cancer Research 2025 27:7
    Content type: Research Published on:

  28. Recent evidence indicates that endocrine resistance in estrogen receptor-positive (ER+) breast cancer is closely correlated with phenotypic characteristics of epithelial-to-mesenchymal transition (EMT). Noneth...

    Authors: Kaimin Hu, Yinan Wu, Yajing Huang, Meiqi Zhou, Yanyan Wang and Xingru Huang
    Citation: Breast Cancer Research 2025 27:6
    Content type: Research Published on:

  29. Alcohol intake is associated with a higher risk of estrogen receptor-positive (ER+) breast cancer (BC), presumably through its confirmed ability to increase sex hormone levels. Whether consuming alcohol within...

    Authors: Elizabeth Mostofsky, Julie E. Buring, Steven E. Come, Nadine M. Tung, Cancan Zhang and Kenneth J. Mukamal
    Citation: Breast Cancer Research 2025 27:5
    Content type: Research Published on:

  30. Patients with estrogen receptor (ER)-positive breast cancer (BC) can be treated with endocrine therapy targeting ER, however, metastatic recurrence occurs in 25% of the patients who have initially been treated...

    Authors: Seung-Su Kim, Issac Park, Jeesoo Kim, Na-Lee Ka, Ga Young Lim, Mi-Ye Park, Sewon Hwang, Ji-Eun Kim, So Yeon Park, Jong-Seo Kim, Hyun-Woo Rhee and Mi-Ock Lee
    Citation: Breast Cancer Research 2025 27:4
    Content type: Research Published on:

  31. Authors: Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park and Yoon-La Choi
    Citation: Breast Cancer Research 2025 27:3
    Content type: Correction Published on:

    The original article was published in Breast Cancer Research 2024 26:13

  32. Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecula...

    Authors: Zhihao Fang, Guohong Ren, Shouyu Ke, Qimin Xu, Yuhua Chen, Xiaoyuan Shi, Cheng Guo and Jian Huang
    Citation: Breast Cancer Research 2025 27:2
    Content type: Research Published on:

  33. Epidemiological studies associate an increase in breast cancer risk, particularly triple-negative breast cancer (TNBC), with lack of breastfeeding. This is more prevalent in African American women, with signif...

    Authors: Sarmila Majumder, Sanjay Mishra, Neelam Shinde, Maria C. Cuitino, Morgan Bauer, Dinesh Ahirwar, Mustafa M. Basree, Vijaya Bharti, Kate Ormiston, Resham Mawalkar, Sara Alsammerai, Gautam Sarathy, Anna E. Vilgelm, Xiaoli Zhang, Ramesh K. Ganju and Bhuvaneswari Ramaswamy
    Citation: Breast Cancer Research 2025 27:1
    Content type: Research Published on:

  34. Triple negative breast cancer (TNBC) belongs to the worst prognosis of breast cancer subtype probably because of distant metastasis to other organs, e.g. lungs. However, the mechanism underlying TNBC metastasi...

    Authors: Wen-Ke Wang, Hui-Yu Lin, Che-Hsuan Lin, Hsun-Hua Lee, Yen-Lin Chen, Yu-Hsien Kent Lin, Hui-Wen Chiu, Shry-Ming Sheen-Chen and Yuan-Feng Lin
    Citation: Breast Cancer Research 2024 26:193
    Content type: Research Published on:

  35. Primary luminal breast cancer cells lose their identity rapidly in standard tissue culture, which is problematic for testing hormone interventions and molecular pathways specific to the luminal subtype. Breast...

    Authors: Róża K. Przanowska, Najwa Labban, Piotr Przanowski, Russell B. Hawes, Kristen A. Atkins, Shayna L. Showalter and Kevin A. Janes
    Citation: Breast Cancer Research 2024 26:192
    Content type: Research Published on:

  36. Substantial evidence supports that delay of surgery after breast cancer diagnosis is associated with increased mortality risk, leading to the introduction of a new Commission on Cancer quality measure for rece...

    Authors: Macall Leslie Salewon, Rashmi Pathak, William C. Dooley, Ronald A. Squires, Hallgeir Rui, Inna Chervoneva and Takemi Tanaka
    Citation: Breast Cancer Research 2024 26:191
    Content type: Research Published on:

  37. Autophagy, a crucial process in cancer, is closely intertwined with both tumor progression and drug resistance development. However, existing methods used to assess autophagy activity often pose invasiveness a...

    Authors: Chiao-Chun Liao, Yuqing Long, Ming-Lin Tsai, Chun-Yu Lin, Kai-Wen Hsu and Chia-Hwa Lee
    Citation: Breast Cancer Research 2024 26:190
    Content type: Research Published on:

  38. The 313-variant polygenic risk score (PRS313) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS313 across different European populations which could influence ri...

    Authors: Kristia Yiangou, Nasim Mavaddat, Joe Dennis, Maria Zanti, Qin Wang, Manjeet K. Bolla, Mustapha Abubakar, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Adinda Baten, Sabine Behrens…
    Citation: Breast Cancer Research 2024 26:189
    Content type: Research Published on:

  39. Depression among breast cancer survivors is a significant concern affecting their long-term survivorship and quality of life. This study investigates the incidence of depression among breast cancer survivors a...

    Authors: Hea Lim Choi, Su Min Jeong, Keun Hye Jeon, Bongseong Kim, Wonyoung Jung, Ansuk Jeong, Kyungdo Han and Dong Wook Shin
    Citation: Breast Cancer Research 2024 26:188
    Content type: Research Published on:

  40. Treatment options for triple-negative breast cancer (TNBC) are limited and patients face a poor prognosis. Here, we sought to identify drugs that target TNBC vulnerabilities and understand the biology underlyi...

    Authors: Nomeda Girnius, Aylin Z. Henstridge, Benjamin Marks, Jeffrey K. Yu, G. Kenneth Gray, Chris Sander, Ioannis K. Zervantonakis and Augustin Luna
    Citation: Breast Cancer Research 2024 26:187
    Content type: Research Published on:

  41. Bone is the most frequent site of metastasis for breast cancer (BC). Metastatic BC cells interact with bone cells, including osteoclasts and osteoblasts, creating a cancer niche where they seed and proliferate...

    Authors: Margherita Puppo, Martine Croset, Davide Ceresa, Manoj Kumar Valluru, Victor Gabriel Canuas Landero, Monserrat Hernandez Guadarrama, Michele Iuliani, Francesco Pantano, Penelope Dawn Ottewell and Philippe Clézardin
    Citation: Breast Cancer Research 2024 26:186
    Content type: Research Published on:

  42. The HOXB13/IL17RB gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is the primar...

    Authors: Irene Rin Mitsiades, Maristela Onozato, A. John Iafrate, Daniel Hicks, Doğa C. Gülhan, Dennis C. Sgroi and Esther Rheinbay
    Citation: Breast Cancer Research 2024 26:185
    Content type: Research Published on:

  43. Human mammary epithelial cell (HMEC) cultures encounter a stress-associated barrier termed stasis, during which most cells adopt a senescence-like phenotype. From these cultures, rare variants emerge from the ...

    Authors: Joseph A. Caruso, Chira Chen-Tanyolac and Thea D. Tlsty
    Citation: Breast Cancer Research 2024 26:184
    Content type: Research Published on:

  44. Basal-like breast cancer originates in luminal progenitors, frequently with an altered PI3K pathway, and focally in close association with genetically altered myoepithelial cells at the site of tumor initiatio...

    Authors: Katharina Theresa Kohler, Jiyoung Kim, René Villadsen, Lone Rønnov-Jessen and Ole William Petersen
    Citation: Breast Cancer Research 2024 26:183
    Content type: Research Published on:

  45. Immunochemotherapy with pembrolizumab has been integrated into clinical practice as part of the standard-of-care for non-metastatic triple-negative breast cancer (TNBC) with high risk. We conducted a real-worl...

    Authors: Soong June Bae, Jee Hung Kim, Min Ji Kim, Yoonwon Kook, Seung Ho Baek, Jung Hyun Kim, Sohyun Moon, Seung Eun Lee, Joon Jeong, Yoon Jin Cha and Sung Gwe Ahn
    Citation: Breast Cancer Research 2024 26:182
    Content type: Research Published on:

  46. Intraoperative radiotherapy (IORT) is a convenient treatment techniques for patients with early-stage breast cancer. We aimed to compare the outcome of IORT to that of whole-breast external beam radiotherapy (...

    Authors: Shi-Yu Gao, Ting-Chun Lin, Liang-Chih Liu, Wen-Ling Chen and Ji-An Liang
    Citation: Breast Cancer Research 2024 26:181
    Content type: Research Published on:

  47. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays a critical role in disease progression and treatment response in triple-negative breast cancers (TNBCs). This study ...

    Authors: Eunkyung Han, Hye Yeon Choi, Hyun Jung Kwon, Yul Ri Chung, Hee-Chul Shin, Eun-Kyu Kim, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim and So Yeon Park
    Citation: Breast Cancer Research 2024 26:180
    Content type: Research Published on:

  48. Because alcohol consumption is an established cause of female breast cancer, understanding whether cessation affects risk is of public health importance. In a recent meta-analysis, compared with continuing con...

    Authors: Mary Beth Terry, Dallas R. English, Jo L. Freudenheim, Béatrice Lauby-Secretan and Susan M. Gapstur
    Citation: Breast Cancer Research 2024 26:179
    Content type: Brief Report Published on:

  49. Ductal carcinoma in-situ (DCIS) is a pre-invasive form of invasive breast cancer (IBC). Due to improved breast cancer screening, it now accounts for ~ 25% of all breast cancers. While the treatment success rat...

    Authors: Marija Debeljak, Soonweng Cho, Bradley M. Downs, Michael Considine, Brittany Avin-McKelvey, Yongchun Wang, Phillip N. Perez, William E. Grizzle, Katherine A. Hoadley, Charles F. Lynch, Brenda Y. Hernandez, Paul J. van Diest, Wendy Cozen, Ann S. Hamilton, Debra Hawes, Edward Gabrielson…
    Citation: Breast Cancer Research 2024 26:178
    Content type: Research Published on:

  50. Breast cancer subtypes Luminal A and Luminal B are classified by the expression of PAM50 genes and may benefit from different treatment strategies. Machine learning models based on H&E images may contain featu...

    Authors: Dong Neuck Lee, Yao Li, Linnea T. Olsson, Alina M. Hamilton, Benjamin C. Calhoun, Katherine A. Hoadley, J. S. Marron and Melissa A. Troester
    Citation: Breast Cancer Research 2024 26:177
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.1
    5-year Journal Impact Factor: 7.1
    Source Normalized Impact per Paper (SNIP): 1.865
    SCImago Journal Rank (SJR): 2.578

    Speed 2024
    Submission to first editorial decision (median days): 12
    Submission to acceptance (median days): 145

    Usage 2024
    Downloads: 2,971,481
    Altmetric mentions: 1,091

Breast Cancer Research

ISSN: 1465-542X

Contact us